ECE2022 Eposter Presentations Pituitary and Neuroendocrinology (211 abstracts)
Predictive factors of biological remission in patients with prolactinoma treated with dopamine agonists
Mouna Elleuch , Hamdi Frikha , Loukil Fatma , Dhoha Ben Salah , Matiem Souissi , Fatma Mnif , Mouna Mnif , Nadia Charfi , Nabila Rekik Majdoub , Faten Haj Kacem Akid & Mohamed Abid
Hedi Chaker University Hospital, Department of Endocrinology, Sfax, Tunisia
Introduction and aim: Dopamine agonists (DA) are prescribed as first-line treatment for prolactinomas and are generally effective and well tolerated. However, the degree and quickness of therapeutic response is variable among patients. The aim of this work is to study the predictive factors of biological remission in patients with prolactinoma treated with DA.
Methods: A single-center, retrospective and analytical study of patients with prolactinoma followed in the endocrinology department of Hedi Chaker University Hospital of Sfax, Tunisia between 2000 and 2020. Biological remission was defined as prolactinemia <25 ng/ml.
Results: We enrolled 69 patients. Patients were predominantly female (69%), aged 38.1 ±14.5 years at diagnosis. One third of patients were obese. Mean initial prolactinemia was 2790.4 ±10780 ng/ml. Adenomas were classified as follows: 24 microprolactinomas, 29 macroprolacinomas and 16 giant prolactinomas. Bromocriptine was prescribed in 46 cases while the remaining were treated with cabergoline. Biological remission was obtained in 24 patients at 6 months of treatment (34.8%) and reached 65.2% at 12 months. Univariate analysis shoewed that the use of cabergoline was significantly associated with remission at 6 months and 12 months (P<0.001). The effect of age reached statistical significance at 12 months (P=0.05). Using multivariate analysis, factors associated with remission at 6 months were cabergoline use only (P=0.04, OR=6) while those that significantly influenced remission at 12 months were cabergoline use (P=0.005, OR=11) and tumor size at diagnosis (P=0.028, OR=1.2, IC[1.02;1.35]). In this series sex and BMI were not significant markers of remission both in univariate and multivariate models.
Conclusion: Cabergoline has proven to be a safe and effective treatment for prolactinomas. Cost and affordability remain major barriers in developing countries.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more